Abstract:Topic: 8. Chronic myeloid leukemia - Clinical Background: Since the SARS-CoV-2 Omicron variant became the predominant virus strain circulating in late 2021, rare data on coronavirus disease 2019 (COVID-19) in patients with chronic myeloid leukemia (CML) in the Omicron era were reported. Aims: We aim to explore the prevalence and severity of COVID-19 cause by Omicron variant and variables associated with them in CML patients during the pandemic. Methods: We performed a cross-sectional survey from 2540 CML patients with age of ≥ 16 years from December 15, 2022, to February 15, 2023 covering the peak of COVID-19 epidemic collected through an online questionnaire. Results: In 2540 respondents, 1425 (56%) were male. The median age was 46 years (interquartile range [IQR], 36–56 years). 1655 (65%) reported they had COVID-19 during this period. Among them, 1554 (94%) were mild COVID-19; 94 (6%), moderate; 7 (0.4%), severe; no critical case or death. 20 (1%) were hospitalized including 3 (0.2%) with mechanical ventilation, and all were discharged within 2-3 weeks. The median length of hospitalization was 5 days (IQR, 5–11 days). In multivariate analyses longer TKI therapy duration was significantly-associated with a lower prevalence of COVID-19 (odds ratio [OR] = 0.98; 95% Confidence Interval [CI], 0.95, 1.00; p = 0.043); however, living in the urban area (OR = 1.6 [1.3-2.1]; p < 0.001) and having family member with COVID-19 (OR = 18.2 [14.8-22.3]; p < 0.001), higher prevalence of COVID-19. Old age (OR = 1.2 [1.0, 2.4]; p = 0.017), having comorbidity(ies) (OR = 1.7 [1.1, 2.7]; p = 0.019), and multi-TKI-resistant patients receiving 3rd generation TKI or investigational agents (OR = 2.2 [1.2, 4.2]; p = 0.011) were significantly-associated with a higher risk of moderate or severe COVID-19. Summary/Conclusion: In conclusion, patients with CML with shorter TKI therapy duration, old age, comorbidity(ies), or multi-TKI-resistant patients with CML receiving 3rd generation TKI or investigational agents had a higher prevalence of COVID-19 or higher risk of moderate or severe disease in the Omicron era. Keywords: Chronic myeloid leukemia, COVID-19, Tyrosine kinase inhibitor

Pb1969: patients with chronic myeloid leukemia and coronavirus disease 2019 in the omicron era